Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Southern California
With
Ortho Biotech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologic diagnosis of Non-Hodgkin's lymphoma of B-cell origin: follicular large cell, diffuse large cell (including all B-cell variants), Burkitt or Burkitt-like lymphoma
All stages of disease
Measurable or evaluable tumor parameter(s)
Age greater than 17 years old
Karnofsky performance status greater or equal to 50%
AGC greater or equal to 1.0; platelets greater or equal to 75,000(unless abnormal because of lymphoma)
Bilirubin less or equal to 2.0; SGOT less or equal to 3 times upper limit of normal (unless abnormal because of lymphoma)
Creatinine less or equal to 2.0 or creatinine clearance greater or equal to 60 ml/min (unless abnormal because of lymphoma)
LVEF greater or equal to 45%
Concurrent RT with or without steroids for emergency conditions secondary to lymphoma (i.e., CNS tumor, cord compression)are permitted
Men and women of childbearing potential must agree to use adequate birth control for the duration of the therapy and for 3 months after completion of therapy
Signed informed consent
You may not be if
Prior systemic cytotoxic therapy or RT for lymphoma
Second active tumor, other than non-melanomatous skin ca and in-situ cervical cancer
HIV seropositive
Primary CNS lymphoma
Pregnant or nursing women
Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent, in the opinion of the PI
Clareo Health | Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
